Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial enrolls participants for the following cohorts based on condition: 1. Epithelial tumors of nasal cavity, sinuses, nasopharynx: A) Squamous cell carcinoma with variants of nasal cavity, sinuses, and nasopharynx and trachea (excluding laryngeal, nasopharyngeal cancer [NPC], and squamous cell carcinoma of the head and neck [SCCHN]) B) Adenocarcinoma and variants of nasal cavity, sinuses, and nasopharynx (closed to accrual 07/27/2018) 2. Epithelial tumors of major salivary glands (closed to accrual 03/20/2018) 3. Salivary gland type tumors of head and neck, lip, esophagus, stomach, trachea and lung, breast and other location (closed to accrual) 4. Undifferentiated carcinoma of gastrointestinal (GI) tract 5. Adenocarcinoma with variants of small intestine (closed to accrual 05/10/2018) 6. Squamous cell carcinoma with variants of GI tract (stomach small intestine, colon, rectum, pancreas) (closed to accrual 10/17/2018) 7. Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary (closed to accrual 03/20/2018) 8. Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. Pancreatic adenocarcinoma is not eligible (closed to accrual) 9. Intrahepatic cholangiocarcinoma (closed to accrual 03/20/2018) 10. Extrahepatic cholangiocarcinoma and bile duct tumors (closed to accrual 03/20/2018) 11. Sarcomatoid carcinoma of lung 12. Bronchoalveolar carcinoma lung. This condition is now also referred to as adenocarcinoma in situ, minimally invasive adenocarcinoma, lepidic predominant adenocarcinoma, or invasive mucinous adenocarcinoma 13. Non-epithelial tumors of the ovary: A) Germ cell tumor of ovary B) Mullerian mixed tumor and adenosarcoma (closed to accrual 03/30/2018) 14. Trophoblastic tumor: A) Choriocarcinoma (closed to accrual) 15. Transitional cell carcinoma other than that of the renal, pelvis, ureter, or bladder (closed to accrual) 16. Cell tumor of the testes and extragonadal germ tumors: A) Seminoma and testicular sex cord cancer B) Non seminomatous tumor C) Teratoma with malignant transformation (closed to accrual) 17. Epithelial tumors of penis - squamous adenocarcinoma cell carcinoma with variants of penis (closed to accrual) 18. Squamous cell carcinoma variants of the genitourinary (GU) system 19. Spindle cell carcinoma of kidney, pelvis, ureter 20. Adenocarcinoma with variants of GU system (excluding prostate cancer) (closed to accrual 07/27/2018) 21. Odontogenic malignant tumors 22. Pancreatic neuroendocrine tumor (PNET) (formerly named: Endocrine carcinoma of pancreas and digestive tract.) (closed to accrual) 23. Neuroendocrine carcinoma including carcinoid of the lung (closed to accrual 12/19/2017) 24. Pheochromocytoma, malignant (closed to accrual) 25. Paraganglioma (closed to accrual 11/29/2018) 26. Carcinomas of pituitary gland, thyroid gland parathyroid gland and adrenal cortex (closed to accrual) 27. Desmoid tumors 28. Peripheral nerve sheath tumors and NF1-related tumors (closed to accrual 09/19/2018) 29. Malignant giant cell tumors 30. Chordoma (closed to accrual 11/29/2018) 31. Adrenal cortical tumors (closed to accrual 06/27/2018) 32. Tumor of unknown primary (Cancer of Unknown Primary; CuP) (closed to accrual 12/22/2017) 33. Not Otherwise Categorized (NOC) Rare Tumors [To obtain permission to enroll in the NOC cohort, contact: S1609SC@swog.org] (closed to accrual 03/15/2019) 34. Adenoid cystic carcinoma (closed to accrual 02/06/2018) 35. Vulvar cancer (closed to accrual) 36. MetaPLASTIC carcinoma (of the breast) (closed to accrual) 37. Gastrointestinal stromal tumor (GIST) (closed to accrual 09/26/2018) 38. Perivascular epithelioid cell tumor (PEComa) 39. Apocrine tumors/extramammary Paget's disease (closed to accrual) 40. Peritoneal mesothelioma 41. Basal cell carcinoma (temporarily closed to accrual 04/29/2020) 42. Clear cell cervical cancer 43. Esthenioneuroblastoma (closed to accrual) 44. Endometrial carcinosarcoma (malignant mixed Mullerian tumors) (closed to accrual) 45. Clear cell endometrial cancer 46. Clear cell ovarian cancer (closed to accrual) 47. Gestational trophoblastic disease (GTD) 48. Gallbladder cancer 49. Small cell carcinoma of the ovary, hypercalcemic type 50. PD-L1 amplified tumors 51. Angiosarcoma 52. High-grade neuroendocrine carcinoma (pancreatic neuroendocrine tumor [PNET] should be enrolled in Cohort 22; prostatic neuroendocrine carcinomas should be enrolled into Cohort 53). Small cell lung cancer is not eligible (closed to accrual) 53. Treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC)


Clinical Trial Description

PRIMARY OBJECTIVES: I. To evaluate the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy. II. To evaluate the overall response rate (ORR) in patients with gestational trophoblastic tumors treated with ipilimumab plus nivolumab combination immunotherapy. III. To evaluate the RECIST v1.1 overall response rate (ORR) in patients PD-L1 amplified cancers treated with nivolumab immunotherapy. SECONDARY OBJECTIVES: I. To evaluate toxicities in each cohort. II. To estimate overall survival (OS), progression-free survival (PFS), clinical benefit rate; and to estimate immune related (i)RECIST ORR (iORR), and iRECIST PFS (iPFS) across cohorts and within each cohort. OUTLINE: Patients are assigned to 1 of 2 arms. ARM I (ALL COHORTS EXCEPT THE PD-L1 AMPLIFIED COHORT): Patients receive nivolumab intravenously (IV) over 30 minutes on days 1, 15, and 29 and ipilimumab IV over 60 minutes on day 1. Treatment repeats every 42 days for up to 17 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who complete 17 cycles (2 years) of therapy, may continue receiving the same treatment with nivolumab and ipilimumab, or receive nivolumab once every 14 or 28 days (2 weeks or 4 weeks) per physician discretion in the absence of disease progression or unacceptable toxicity. Patients who stop treatment prior to the completion of 17 cycles of therapy may receive nivolumab once every 14 or 28 days (2 weeks or 4 weeks) in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography (ECHO) during screening and on study. Patients also undergo magnetic resonance imaging (MRI) or computed tomography (CT) throughout the trial. Additionally, patients undergo blood sample collection throughout the trial. ARM II (PD-L1 AMPLIFIED COHORT): Patients receive nivolumab IV over 30 minutes on days 1, 15 and 29. Treatment repeats every 42 days for up to 17 cycles (2 years) in the absence of disease progression or unacceptable toxicity. After 17 cycles (2 years) of therapy, patients may receive nivolumab once every 14 or 28 days (2 weeks or 4 weeks) in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO during screening and on study. Patients also undergo MRI or CT throughout the trial. Additionally, patients undergo blood sample collection throughout the trial. After completion of study treatment, patients are followed up for 10 years from registration. ;


Study Design


Related Conditions & MeSH terms

  • Acinar Cell Carcinoma
  • Adenocarcinoma
  • Adenocarcinoma of Lung
  • Adenocarcinoma, Bronchiolo-Alveolar
  • Adenocarcinoma, Mucinous
  • Adenocarcinoma, Papillary
  • Adenoid Cystic Carcinoma
  • Adrenal Cortical Carcinoma
  • Adrenal Gland Pheochromocytoma
  • Adrenocortical Carcinoma
  • Anal Canal Neuroendocrine Carcinoma
  • Anal Canal Undifferentiated Carcinoma
  • Angiosarcoma
  • Apocrine Neoplasm
  • Appendix Mucinous Adenocarcinoma
  • Bartholin Gland Transitional Cell Carcinoma
  • Basal Cell Carcinoma
  • Bladder Adenocarcinoma
  • Breast Metaplastic Carcinoma
  • Carcinoma
  • Carcinoma, Adenoid Cystic
  • Carcinoma, Basal Cell
  • Carcinoma, Endometrioid
  • Carcinoma, Giant Cell
  • Carcinoma, Islet Cell
  • Carcinoma, Neuroendocrine
  • Carcinoma, Squamous Cell
  • Carcinoma, Transitional Cell
  • Cervical Adenocarcinoma
  • Cholangiocarcinoma
  • Chordoma
  • Choriocarcinoma
  • Colorectal Squamous Cell Carcinoma
  • Cystadenocarcinoma
  • Desmoid Fibromatosis
  • Endometrial Transitional Cell Carcinoma
  • Endometrioid Adenocarcinoma
  • Esophageal Neuroendocrine Carcinoma
  • Esophageal Undifferentiated Carcinoma
  • Extrahepatic Bile Duct Carcinoma
  • Extramammary Paget Disease
  • Fallopian Tube Adenocarcinoma
  • Fallopian Tube Transitional Cell Carcinoma
  • Fibroma
  • Fibromyxoid Tumor
  • Gallbladder Carcinoma
  • Gastric Neuroendocrine Carcinoma
  • Gastric Squamous Cell Carcinoma
  • Gastric Undifferentiated Carcinoma
  • Gastrointestinal Stromal Tumor
  • Gastrointestinal Stromal Tumors
  • Gestational Trophoblastic Tumor
  • Giant Cell Carcinoma
  • Intestinal Neuroendocrine Carcinoma
  • Intrahepatic Cholangiocarcinoma
  • Lung Sarcomatoid Carcinoma
  • Major Salivary Gland Carcinoma
  • Malignant Odontogenic Neoplasm
  • Malignant Peripheral Nerve Sheath Tumor
  • Malignant Solid Neoplasm
  • Malignant Testicular Sex Cord-Stromal Tumor
  • Metastatic Malignant Neoplasm of Unknown Primary
  • Minimally Invasive Lung Adenocarcinoma
  • Mixed Mesodermal (Mullerian) Tumor
  • Mixed Tumor, Mullerian
  • Mucinous Adenocarcinoma
  • Mucinous Cystadenocarcinoma
  • Nasal Cavity Adenocarcinoma
  • Nasal Cavity Carcinoma
  • Nasopharyngeal Carcinoma
  • Nasopharyngeal Undifferentiated Carcinoma
  • Neoplasms
  • Neoplasms, Germ Cell and Embryonal
  • Neoplasms, Unknown Primary
  • Nerve Sheath Neoplasms
  • Neuroendocrine Tumors
  • Oral Cavity Carcinoma
  • Oropharyngeal Undifferentiated Carcinoma
  • Ovarian Adenocarcinoma
  • Ovarian Germ Cell Tumor
  • Ovarian Mucinous Adenocarcinoma
  • Ovarian Squamous Cell Carcinoma
  • Ovarian Transitional Cell Carcinoma
  • Paget Disease, Extramammary
  • Pancreatic Acinar Cell Carcinoma
  • Pancreatic Neuroendocrine Carcinoma
  • Paraganglioma
  • Paranasal Sinus Adenocarcinoma
  • Paranasal Sinus Carcinoma
  • Parathyroid Gland Carcinoma
  • PEComa
  • Penile Squamous Cell Carcinoma
  • Pheochromocytoma
  • Placental Choriocarcinoma
  • Primary Peritoneal High Grade Serous Adenocarcinoma
  • Pseudomyxoma Peritonei
  • Rare Disorder
  • Scrotal Squamous Cell Carcinoma
  • Seminal Vesicle Adenocarcinoma
  • Seminoma
  • Serous Cystadenocarcinoma
  • Small Intestinal Adenocarcinoma
  • Small Intestinal Squamous Cell Carcinoma
  • Spindle Cell Neoplasm
  • Teratoma
  • Teratoma With Somatic-Type Malignancy
  • Testicular Non-Seminomatous Germ Cell Tumor
  • Thyroid Gland Carcinoma
  • Thyroid Neoplasms
  • Tracheal Carcinoma
  • Transitional Cell Carcinoma
  • Trophoblastic Neoplasms
  • Ureter Adenocarcinoma
  • Ureter Squamous Cell Carcinoma
  • Urethral Adenocarcinoma
  • Urethral Squamous Cell Carcinoma
  • Vaginal Adenocarcinoma
  • Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
  • Vulvar Carcinoma
  • Vulvar Neoplasms

NCT number NCT02834013
Study type Interventional
Source National Cancer Institute (NCI)
Contact
Status Active, not recruiting
Phase Phase 2
Start date January 30, 2017
Completion date May 1, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT05979961 - Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Recruiting NCT06055816 - Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma Phase 2
Recruiting NCT05547971 - Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics
Not yet recruiting NCT05020925 - SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 1/Phase 2
Not yet recruiting NCT04548271 - Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 2
Not yet recruiting NCT04547088 - Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 2
Recruiting NCT02795169 - Trail Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma Phase 1/Phase 2
Terminated NCT02569788 - Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma Phase 1/Phase 2
Terminated NCT02801487 - Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma Phase 1/Phase 2
Completed NCT02237924 - Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma Phase 2
Recruiting NCT02044562 - Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients N/A
Terminated NCT01694576 - NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation Phase 2
Recruiting NCT01462903 - A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors Phase 1
Completed NCT01271439 - Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma Phase 2
Completed NCT00535795 - Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA Phase 3
Completed NCT00379262 - Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma Phase 3
Completed NCT03398980 - Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiotherapy N/A
Completed NCT01309633 - Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC) Phase 2